News >

Ibrutinib Regimen Extends PFS in Phase III CLL Study

Silas Inman @silasinman
Published: Tuesday, Mar 17, 2015

Peripheral blood smear showing CLL cellsThe phase III HELIOS study examining ibrutinib in combination with bendamustine and rituximab (BR) has been unblinded following the demonstration of a significant extension in progression-free survival (PFS) with the triplet compared with BR alone in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication